Literature DB >> 23132402

Simultaneous inhibition of COX-2 and activation of PPAR-γ resulted in the same level and pattern of neuroprotection as they were targeted separately.

Shahnaz Babaei Abraki1, Leila Khalaj, Fatemeh Shaerzadeh, Fariba Khodagholi.   

Abstract

The inflammatory response is an immune response of the body when exposed to internal and external stimuli. Cyclooxygenases (COX) are major inflammatory mediators implicated in inflammation. COX-2 is reported to be involved in neuroinflammation. Moreover, 15-Deoxy-D (12,14)-prostaglandin J2 (15d-PGJ2), an endogenous ligand of peroxisome proliferator-activated receptor gamma (PPAR-γ), has been demonstrated to have anti-inflammatory actions. In this study, we investigated whether co-therapy of a selective COX-2 inhibitor NS-398 and 15d-PGJ2 as a PPAR-γ ligand could exert additional neuroprotective effects in rat pheochromocytoma (PC12) cells. Our findings showed that 15d-PGJ2 and NS-398 suppress the apoptotic pathway in PC12 cells exposed to H(2)O(2) by attenuation of the Bax/Bcl-2 ratio. This effect was mediated through PPAR-γ, as it was reversed by GW9662 (a PPAR-γ inhibitor). Also, 15d-PGJ2 and NS-398 induced the Nrf2 signaling pathway and decreased NF-κB level in a PPAR-γ-dependent manner. We found that coadministration of a selective COX-2 inhibitor and a PPAR-γ ligand in PC12 cells has equal neuroprotective effect compared to their effects when used separately. Considering the higher affinity of 15d-PGJ2 for PPAR-γ than NS-398, it seems that the observed neuroprotection of this combination therapy was from 15d-PGJ2.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23132402     DOI: 10.1007/s12031-012-9903-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  57 in total

1.  PPAR tissue distribution and interactions with other hormone-signaling pathways.

Authors:  T Lemberger; O Braissant; C Juge-Aubry; H Keller; R Saladin; B Staels; J Auwerx; A G Burger; C A Meier; W Wahli
Journal:  Ann N Y Acad Sci       Date:  1996-12-27       Impact factor: 5.691

2.  Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration.

Authors:  Heather C Salzberg-Brenhouse; Er-Yun Chen; Dwaine F Emerich; Sam Baldwin; Ken Hogeland; Sharon Ranelli; Denise Lafreniere; Brigido Perdomo; Leah Novak; Theodora Kladis; Karen Fu; Anthony S Basile; Jeffrey H Kordower; Raymond T Bartus
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

3.  15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit.

Authors:  E Cernuda-Morollón; E Pineda-Molina; F J Cañada; D Pérez-Sala
Journal:  J Biol Chem       Date:  2001-07-20       Impact factor: 5.157

Review 4.  Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).

Authors:  Alaa F Badawi; Mostafa Z Badr
Journal:  Int J Oncol       Date:  2002-06       Impact factor: 5.650

Review 5.  Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases.

Authors:  Luisa Minghetti
Journal:  J Neuropathol Exp Neurol       Date:  2004-09       Impact factor: 3.685

Review 6.  Regulation of Nrf2-dependent gene expression by 15-deoxy-Delta12,14-prostaglandin J2.

Authors:  Emilia Kansanen; Annukka M Kivelä; Anna-Liisa Levonen
Journal:  Free Radic Biol Med       Date:  2009-06-30       Impact factor: 7.376

Review 7.  Heme oxygenase-1: the "emerging molecule" has arrived.

Authors:  Danielle Morse; Augustine M K Choi
Journal:  Am J Respir Cell Mol Biol       Date:  2002-07       Impact factor: 6.914

8.  Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells.

Authors:  Takakazu Nagahara; Jun-ichi Okano; Yoshikazu Murawaki
Journal:  Oncol Rep       Date:  2007-11       Impact factor: 3.906

Review 9.  Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.

Authors:  Stephen Gately; Robert Kerbel
Journal:  Prog Exp Tumor Res       Date:  2003

10.  Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.

Authors:  Lichuan Yang; Noel Y Calingasan; Bobby Thomas; Rajnish K Chaturvedi; Mahmoud Kiaei; Elizabeth J Wille; Karen T Liby; Charlotte Williams; Darlene Royce; Renee Risingsong; Eric S Musiek; Jason D Morrow; Michael Sporn; M Flint Beal
Journal:  PLoS One       Date:  2009-06-01       Impact factor: 3.240

View more
  3 in total

1.  Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection.

Authors:  Erwan Thouennon; Yong Cheng; Vida Falahatian; Niamh X Cawley; Yoke Peng Loh
Journal:  J Neurochem       Date:  2015-06-01       Impact factor: 5.372

2.  LPS induces mediators of neuroinflammation, cell proliferation, and GFAP expression in human astrocytoma cells U373MG: the anti-inflammatory and anti-proliferative effect of guggulipid.

Authors:  Rituraj Niranjan; Rajasekar Nagarajan; Kashif Hanif; Chandishwar Nath; Rakesh Shukla
Journal:  Neurol Sci       Date:  2013-09-07       Impact factor: 3.307

3.  Celecoxib-mediated attenuation of non-alcoholic steatohepatitis is potentially relevant to redistributing the expression of adiponectin receptors in rats.

Authors:  Guoying Zhu; Li Chen; Su Liu; Ling She; Yongnian Ding; Changqing Yang; Fengshang Zhu
Journal:  Heliyon       Date:  2022-07-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.